Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers
CEO Tells Scrip Licensing Pact Is Its First, But Not Last
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
